Hematology
Feature
Ongoing research aims to improve transplant outcomes in sickle cell
Over the past 2 years, the majority of novel transplant techniques have been primarily aimed at improving conditioning regimens and lowering rates...
From the Journals
Stem cells gene edited to be HIV resistant treat ALL, but not HIV
Conference Coverage
Early post-ACS bleeding may signal cancer
PARIS – Cancer risk is elevated with bleeding, whether or not DAPT is employed
Pearl of the Month
How thin should we go?
Dr. Douglas S. Paauw describes the best approach to anticoagulation in patients with atrial fibrillation who are on anticoagulation, then have a...
Conference Coverage
RNA interference drug fitusiran looks effective in both hemophilia A and B
MELBOURNE – The RNA interference drug fitusiran is associated with significant reductions in bleeding rates in patients with hemophilia A and B,...
Conference Coverage
Early phase trial shows durable responses to gene therapy for hemophilia A
MELBOURNE – Gene therapy to replace factor VIII in patients with hemophilia has shown sustained reductions in bleeding rates with no significant...
From the Journals
BRCA2 mutations linked to childhood NHL
Survivors of childhood non-Hodgkin may be at significantly increased risk for breast, ovarian, prostate, and other BRCA2-associated cancers.
Conference Coverage
Sickle cell unit running 24/7 reduces readmissions, emergency visits
FORT LAUDERDALE, FLA. – An analysis of an around-the-clock sickle cell unit showed significant reductions in per-patient health care utilization...
Guidelines
First adult APS recommendations released by European society
MADRID – The EULAR recommendations also cover secondary prevention and management of recurrent episodes and catastrophic APS, for which new...
Conference Coverage
Minor surgeries appear safe for hemophilia patients on emicizumab
MELBOURNE – Patients with hemophilia A treated with emicizumab can safely undergo minor surgery, often without needing prophylactic coagulation...
From the Journals
NOACs benefit early stage chronic kidney disease patients
NOACs reduced risk of several adverse events compared with VKAs in a meta-analysis of chronic kidney disease patients.